Monday, 5 October 2020
High Intensity Focused Ultrasound (HIFU) Market Expects An Extensive Growth In Roi Till 2023
Market Highlights
High-intensity focused ultrasound (HIFU) therapy is a novel, emerging, and therapeutic modality technology. It involves propagation of ultrasound waves through cancerous tissues that kills cancer cells. HIFU is a minimal invasive technique and is performed with real-time imaging by ultrasound or MRI to enable treatment targeting and monitoring. This technology have been extensively exploited for the treatment of prostate, liver, pancreatic, and bladder cancer. The American Cancer Society estimated that about 161,360 new cases of prostate cancer have been registered in the US in 2017. Moreover, the number of people living beyond a cancer diagnosis were nearly 14.5 million in 2014 and is expected to rise to over 19 million by 2024. Moreover, increasing development in the medical technology and its wide range of application used in the treatment of uterine fibroids, neurological disorders, cosmetic medicine and others fuel the growth of this market. However, high cost of the treatment and certain adverse effects are likely to restrain the market growth over the forecasted period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/885
The global high intensity focused ultrasound (HIFU) therapy market is expected to grow at a CAGR of 7.8% during the forecast period 2017-2023.
Taste the market data and market information presented through more than 115 market data tables and figures spread over 110 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “high intensity focused ultrasound (HIFU) therapy market research report–Global forecast till 2023.”
Major Players in High intensity focused ultrasound (HIFU) therapy Market
Some of the key players in the global market are Image Guided Therapy, EDAP TMS, SonaCare Medical, LLC, Theraclion, Chongqing Haifu Medical Technology Co., Ltd, Koninklijke Philips N.V., Shanghai A&S Co. LTD, Mianyang Sonic Electronic Ltd., Insightec, Alpinion Medical Systems, and FUS Instruments.
Regional Analysis
The global high intensity focused ultrasound (HIFU) therapy market consists of four regions including the Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas dominates the global HIFU therapy market. North America is the largest market owing to rising prevalence of cancer cases in the American counties and well-developed technology in this region contributes majorly to the growth of this market.
Europe accounts for the second largest share of the global HIFU therapy market. In the Europe, wide demand for cancer diseases treatment methods drives the market growth. Moreover, increasing expenditure in the healthcare domain and investment in research & development in developing new treatment methods for cancer diseases will fuel to the growth of this market.
Asia Pacific is the fastest growing market in the world. India is the largest potential market due to increasing investments in healthcare services and increasing adaption of new technologies used for diagnosis and treatment methods.
The Middle East & Africa is expected to witness a steady growth due to rising demand for primary healthcare services such as new and advanced treatment methods in healthcare domain.
Segmentation
The global high intensity focused ultrasound (HIFU) therapy market has been segmented on the basis of modality, which comprises of therapeutic ultrasound, hemostasis, lithotripsy, thrombolysis, immunomodulation, and others. On the basis of the methods, the market is segmented into non-invasive method and minimal invasive method. On the basis of applications, the market has been segmented into prostate cancer, uterine fibroids, neurological disorders, cosmetic medicine, and others. On the basis of end users, the market has been segmented into diagnostic centers, hospitals, research centers, and others.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/high-intensity-focused-ultrasound-therapy-market-885
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
EMEA Blood Glucose Test Strip Packaging Market 2020 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2021
Market Highlights
In the end, the report introduced medical suction device market SWOT analysis, PEST analysis, market share analysis and competitive landscape, company profiles by analyzing the major players. It is a depth research study on Europe, the Middle East and Africa Blood Glucose Test Strip Packaging Market. We are thankful for the support and assistance from Europe, the Middle East and Africa Blood Glucose Test Strip Packaging Market chain related technical experts and marketing experts during Research Team survey and interviews.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/601
Table Of Contents
1 Introduction
1.1 Definition
1.2 Scope Of The Study
1.2.1 Research Objectives
1.2.2 Assumptions & Limitations
1.3 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
2.4 Forecast Model
3 Report Excerpt
4 Forecast Indicators
4.1 Introduction
4.2 Growth Drivers
4.3 Growth Barriers
4.4 Growth Opportunities
4.5 Macroecnomical Indicators
5 Market Analysis
6 Europe, The Middle East And Africa Blood Glucose Test Strip Market
6.1 Introduction
6.2 By Volume
6.3 By Value
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/europe-blood-glucose-test-strip-packaging-market-601
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Americas Sterility Testing Market Expects An Extensive Growth In Roi Till 2023
Market Highlights
Sterility ensures that the product meets to its superior quality. It is widely used in cell banks and drug testing. All the drugs, substance or any parenteral intended for human use need to be sterile as well as all the preparation intended to human use need to be sterile before they administered to the patients. Sterility testing should be performed in an aseptic condition, which meets the requirement of USP. All the standard procedures and requirement are been mentioned in USP and the organization must meet the requirement for the tests. The testing must be free from any pathogens or contamination to ensure the positive results of the tests. Increasing prevalence of various diseases and introduction of new diseases leads the sterility testing market. It is observed that manufacturers are constantly introducing various new drugs to the market and increasing strong government support flourish the sterility market. Furthermore, to introduce a new drug is a long processes since the drug needs to pass a number of tests before it introduced in the market. Sterility tests are divided into three major category like membrane filtration sterility testing, direct incubation sterility testing, direct transfer, and others. Membrane filtration is the most common test for the sterility testing. Beside this, increasing pharmaceutical and biotechnology companies significantly increasing the market. According to the survey carried out by OECD, 11,367 biotechnological companies were present in the US in 2015 and the number is increasing every year. Moreover, increasing number of companies, increase the sterility test market. On the other hand, high cost of the test, long delayed approvals and improper environmental condition may hamper the sterility market over the projected period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/reports/americas-sterility-testing-market-571
Regional Analysis
The Americas sterility testing market is egmented into North America and South America. North America holds the major share owing to increasing development of new drugs, huge R&D activities, and increasing number of pharmaceutical & biotechnological companies. Increasing prevalence of new diseases has significantly increased the sterility testing market. Increasing government initiatives against such diseases are also providing a push to the market growth. South America owns the least share of the sterility market.
Segmentation
The Americas sterility testing market is segmented on the basis of products, types of test, application, and end users. On basis of type of product, the market is segmented into instrument, reagent & services, kits, and others. On the basis of type of tests, the market is segmented into membrane filtration sterility testing, direct incubation sterility testing, direct transfer, and others. On the basis of application, the market is segmented into pharmaceutical & biological manufacturing, medical devices manufacturing, and others. On the basis of end user, the market is segmented into pharmaceuticals, hospital & laboratories, and other.
Key Players
Some of the major players in the market are Charles River Laboratories International, Inc. (US), Avance Biosciences (US), Boston Scientific Corporation (US), Paragon Bioservices, Inc (US), Thermo Fisher Scientific, Inc. (U.S.), Avista Pharma Solutions (US), DYNALABS LLC. (US), and Merck KGaA (Germany)
Various leading companies such as Thermo Fisher Scientific, Inc. and Charles River Laboratories International, Inc. are in the competition of discovering the new methods for sterility testing. The high saturation of the companies in the market has increased the competition from the last few years.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/americas-sterility-testing-market-571
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Future Scope of Conjunctivitis Drugs Market is Witness to Grow High CAGR till 2025
The Global Conjunctivitis Drugs Market research report provides a comprehensive study for all major regions around the globe on production capacity, consumption, import and export.
Global Conjunctivitis Drugs Market Information, by Conjunctivitis Type (viral, bacterial, allergic and others), by drug class (Antibiotics (Quinolones, Aminoglycosides, Macrolides and others), mast cell stabilizers, steroids and Others, by route of administration (Topical, Oral and Intra-vitreal), by end user (hospitals and self-administered) – Forecast till 2022
Market Research Future published a half-cooked research report on Global Conjunctivitis Drugs Market which is expected to grow at a CAGR of 3.1% from 2016 to 2022.
Market Highlights
Bacterial and viral inflammation are the most common causes of conjunctivitis and is contagious which require treatment. Growing prevalence of viral and bacterial conjunctivitis is the preliminary factor contributing to the growth of the global conjunctivitis market.
Raising awareness regarding the treatment options available for conjunctivitis is a crucial factor aiding the market growth. High awareness has been purveyed by efforts of various international organizations to spread awareness regarding the contagious nature of conjunctivitis and increased focus on eye care.
Other drivers include poor hygiene and lack of awareness regarding the same in developing countries. High unmet medical needs in the developing regions are one of the chief drivers of the market growth. The prevalence of conjunctivitis is surging in the developing regions due to lack of proper hygiene and lack of access to medical treatment options. Raising awareness and greater affordability due to a rise in disposable income further complements the scenario in the developing countries which creates a conducive environment for the growth of the global conjunctivitis market.
Key Players :
The global conjunctivitis drugs market has been evaluated to be growing and it is expected that it will touch high growth figures in future. The global conjunctivitis drugs market is expected to grow with CAGR of 3.1% in future. Market development and diversification into Asian Pacific market seems to have better strategy for the current situation.
- Akorn Pharmaceuticals,
- Alcon/ Novartis AG,
- Allergan Plc,
- Bausch & Lomb,
- Valeant Pharmaceuticals,
- Merck & Co. Inc.,
- Actavis Plc.,
- Pfizer Inc. and others.
Segments :
The global conjunctivitis drugs market has been segmented based on type, drug class, route of administration, and end users. By type, the market has been segmented into viral, bacterial, allergic and others types of the same. By drug class, the market has been segmented into antibiotics (quinolones, aminoglycosides, macrolides, and others), mast cell stabilizers, steroids, and others. By route of administration, the market has been segmented into topical, oral and intravitreal. By end users, the market has been segmented into hospitals and self-administered.
Regional Analysis :
The Americas, Europe, Asia Pacific, and the Middle East & Africa are the key markets for conjunctivitis drugs. The Americas dominate the global conjunctivitis drugs market followed by Europe. The market in the Americas is driven by high awareness regarding the disease and accessibility to advanced treatment options. A high number of ongoing clinical trials boosts the market growth in Europe. However, the market in developed regions such as the Americas and Europe are already matured, and growth in these markets have become stagnant. The developing countries store more potential for growth and will lead the market over the forecast period. The growth in the markets of Asia Pacific and the Middle East & Africa will be ushered by high unmet medical needs, raising awareness and growing prevalence of conjunctivitis in the regions.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/conjunctivitis-drugs-market-2513
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Anemia Drugs Market Foreseen to Draw a Promising Growth by 2022
Recently MRFR, a leading market research firm collated a novel report on “Global Anemia Drugs Market Research Study” that gives comprehensive market overview about the current market dynamics with a focus on the worldwide market.
The Global Anemia Drugs Market is growing with the sound pace. According to a recent study report published by the Market Research Future, the global anemia drugs market is booming and is expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017 – 2022).
The global market for anemia drugs is growing at a good rate. The market driving factors are growth of geriatric population, increasing awareness, increasing focus of social healthcare on women health and particularly anemia, rise in accidents and cancer, rise in other risk factors such as diabetes, modern lifestyle induced stress, poor nutritional habits, rise in lactating and pregnant women in developing regions, intestinal infections etc.
The market constraints are poor absorption of drugs especially intravenous iron and the side effects associated with the treatment. Better nutrition due to rising per capita income is also a market limiting factor for anemic drugs.
Key Players for Global Anemia Drugs Market
Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company are some of the prominent players at the forefront of competition in the global anemia drugs market and are profiled in MRFR Analysis.
Characterized by the presence of several well-established and small players, the global anemia drugs market appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economies, makes it difficult for regional vendors to compete with them, especially in terms of features such as product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
In April-2017, Amgen Inc. expanded their commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration was built on a global neuroscience collaboration in Alzheimer’s disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leveraged Novartis’ strong and established presence in neuroscience to more effectively reach people with migraine.
In December-2015, GlaxoSmithKline plc. announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets.
In October-2016, Elanco U.S., Inc., a subsidiary of Eli Lilly and Company acquired Boehringer Ingelheim Vetmedica, Inc.’s (BIVI) U.S. feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site – for USD 885 million, including the estimated cost of acquired inventory.
Segments for Global Anemia Drugs Market
Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration; market is segmented into oral and injectable. On the basis of gender; market is segmented into male and female. On the basis of product type; market is segmented into biologics and non-biologics. On the basis of end users; market is segmented into hospitals, self-administered and others.
Regional Analysis for Global Anemia Drugs Market
On the regional backgrounds the Americas leads the global market for anemia drugs owing to huge patient population, increasing healthcare expenditures and presence of the developed economies like U.S. and Canada within the region. Following, the same trends Europe is second in the market. The Asia Pacific region is the fastest growing region due to the developing economies like India and China. Middle East and Africa have the least market share, especially due to the presence of poor economies within the African region. Moreover, stringent government policies within the region are restraining the market growth within the region. On the hand, Middle East leads the regional market due to the presence of developed economies like Kuwait, Qatar, and others within the region and rising healthcare expenses.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/anemia-drugs-market-2499
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Future Growth of Hepatitis C Drugs Market is Expected to Grow Healthy CAGR till 2022
Hepatitis C Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.
Hepatitis C Drugs Market 2020 Global Industry Forecast to 2022 Research Report, is latest depth analysis report on Global Hepatitis C Drugs Market Size, Trends, Share, Growth, and Regional Analysis from 2018 to 2022. In this study Hepatitis C Drugs Market is segmented By Drug Class (Anti-Viral, Immuno-modulators and others), By Medicine System (Allopathic, Alternative and Others), By Route of Administration (Oral, Injectable and others) and By End User (Hospitals and Private) – Forecast Till 2022
Hepatitis C Drugs Market Overview:
Global hepatitis C drugs market is expecting a modest CAGR of 3.3% during the forecast period (2015-2022), reveals Market Research Future (MRFR) in a detailed analysis of the same. In the meantime, the hepatitis C drugs market can easily climb a valuation of USD 22721.1 million driven by several market factors such as a substantial increase in government subsidy and reimbursement policy, better screening system in developing nations, unsafe sex, etc. Furthermore, medical negligence such as sharing needles, unsterilized equipment, and a blood transfusion from infected mother to newborn are giving rise to the contraction of hepatitis C which resultantly, is triggering the hepatitis C drugs market growth.
Hepatitis C Drugs Industry Trends:
Direct-acting antivirals or DAAs is now bringing in a change in treating hepatitis C which has a success rate of 70%-99%. The trend is currently sweeping the market with several companies such as Merck and Vertex Pharmaceuticals, Janssen, and Gilead launching their medicines respectively Victrelis (boceprevir) and Incivek (telaprevir), Olysio (simeprevir), and Sovaldi (sofosbuvir).
Hepatitis C Drugs Market Segmentation:
The global hepatitis c drugs market can be segmented by drug class, medicine system, route of administration, and end-users.
On the basis of drug class, the hepatitis c drugs market comprises anti-viral, immuno-modulators and others.
Based on the medicine system, the hepatitis c drugs market can be segmented into allopathic, alternative and others.
Based on the route of administration, the hepatitis c drugs market can be segmented into oral, injectable and others.
Based on end-users, the hepatitis c drugs market includes hospitals and private.
Hepatitis C Drugs Market Regional Analysis:
Geographical analysis of the hepatitis C drugs market covers chiefly the Americas, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA).
The Americas is, at present, commanding the market with the maximum amount of revenue share. Its excellent healthcare facilities and superior research & development infrastructure are bound to set the future market rolling for the hepatitis C drugs market. At the same time, private investors are spending substantially to develop new drugs which can further improve the market scenario.
Europe is the second largest market. However, like other developed countries from the Americas, this region too can witness a plummeting of CAGR as the market can remain stagnant due to the decreasing number of patients. However, drug companies are mostly based out of the Americas or Europe which can aid the regional market growth. The APAC region can expect China and India to lead the market. Their huge population can substantially promote the market. However, technological advancement has caused a drop in the number of patients, and the regional market can only record moderate growth.
Hepatitis C Drugs Market Insight:
The global hepatitis C drugs market is witnessing growth owing to strategic implementations such as mergers, collaborations, acquisitions, and other methods. Pharmaceutical companies in Latin America are now tying up with non-profit organizations will manufacture and supply new and affordable hepatitis C drugs. Gilead, on the other hand, is launching a generic version of their Epclusa, 10 years prior for better production and selling cost alignment.
Some of the key players in this hepatitis C drugs market are Gilead Sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche Ltd., and others.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/hepatitis-c-drugs-market-2487
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312